Quantcast

Latest Diabetes Stories

2014-06-14 12:20:58

During the 1-year program, patients showed statistically significant reductions in blood glucose levels, increased belief in their ability to self-manage their diabetes and improved perceptions of support, while the community showed statistically significant increases in diabetes awareness SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- The American Academy of Family Physicians Foundation announced today that the Cities for Life program, supported by Sanofi US, helped decrease blood glucose...

2014-06-14 12:20:53

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Data from a new phase 3 study demonstrated that once-daily Victoza(R) (liraglutide [rDNA origin] injection) provided greater glycaemic control versus placebo with no worsening of renal function in adults with type 2 diabetes and moderate renal impairment.[1],[2] The data were presented today at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, CA. Renal impairment is one of the more...

2014-06-14 12:20:50

Data Presented at ADA Scientific Sessions Suggest DRI May Enable More Timely and Focused Risk Assessment and Intervention in At-risk Patients SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced the presentation of data demonstrating the utility of the company's...

2014-06-14 12:20:48

CSO Dr. Peter Daddona to Share Data on Use of ZP-Glucagon Product Candidate in Healthy Volunteers FREMONT, Calif., June 14, 2014 /PRNewswire/ -- Zosano Pharma, Inc., a privately held biopharmaceutical company developing products based on its novel transdermal delivery technology, announced that Peter Daddona, Ph.D., Chief Scientific Officer and Executive Vice President, Research & Development, will present data today on its ZP-Glucagon product candidate at the 74(th) American...

2014-06-14 12:20:45

Once-Weekly Dulaglutide 1.5 mg Also Demonstrates Weight Loss, Low Rates of Hypoglycemia in AWARD-6 Trial SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released detailed results from dulaglutide's sixth AWARD trial, showing that once-weekly dulaglutide 1.5 mg was non-inferior to once-daily liraglutide 1.8 mg. The non-inferiority study demonstrated similar reductions in average blood sugar levels (HbA1c) across both arms.(1) The head-to-head study compared...

2014-06-14 12:20:43

Data presented at the 74th American Diabetes Association Scientific Sessions® expand body of evidence for the mechanism of action of basal insulin peglispro in healthy human subjects SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data regarding the mechanism of action of basal insulin peglispro (BIL). When BIL and insulin glargine were each administered to achieve complete suppression of glucose production, which principally comes from the...

2014-06-14 12:20:40

Companies present comprehensive data for LY2963016, investigational new insulin glargine product SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- For the first time today, Eli Lilly and Company (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals Inc. presented data showing that LY2963016, the alliance's investigational new insulin glargine product, has a similar safety and efficacy profile to currently marketed insulin glargine (Lantus(®)).(1,2,3,4,5,6) Results from these Phase I and Phase III...

2014-06-14 12:20:36

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment of people with type 2 diabetes, maintained its glucose-lowering effect and confirmed safety evaluations for up to one year.[1] Findings from the 26-week extension of the DUAL(TM) I clinical trial programme were presented today at the 74th Annual Scientific Sessions of the American...

2014-06-14 12:20:29

Data also showed liraglutide 3 mg improved blood glucose control compared to placebo at 56 weeks SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Today, primary results from SCALE(TM) Diabetes, a phase 3a clinical trial of liraglutide 3 mg, an investigational once-daily glucagon-like peptide-1 (GLP-1) analogue for chronic weight management, were presented for the first time at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco,...

2014-06-13 23:07:52

Blood Sugar Blueprint helps people control their blood sugar levels fast and effortlessly. An overview on the website Vinaf.com shows if the program is worth buying. New York, NY (PRWEB) June 13, 2014 Blood Sugar Blueprint is a new program developed by Dan Solomon & Bill Savage, the well-known diabetes experts, who have many years of experience in the health industry. The program provides people will discover natural remedies and detailed instructions on how to control their blood...


Latest Diabetes Reference Libraries

Diabetes (journal)
2012-05-12 21:44:48

Diabetes is a peer-reviewed medical journal published since 1952 by the American Diabetes Association. Diabetes is a separate journal from the journal Diabetes Care, which is also published by the ADA. Diabetes covers research about the physiology and pathophysiology of diabetes mellitus, including any aspect of laboratory, animal or human research. Emphasis is on investigative reports focusing on areas such as the pathogenesis of diabetes and its complications, normal and pathologic...

Diabetes Care
2012-05-12 21:41:27

Diabetes Care is a peer-reviewed medical journal established in 1978 and published monthly by the American Diabetes Association. It covers research in the following five categories: clinical care/education/nutrition/psychosocial research; epidemiology/health services research; emerging treatments and technologies; pathophysiology/complications; and cardiovascular and metabolic risk. The journal also publishes clinically relevant review articles, letters to the editor, and commentaries....

0_0d961f30bdfa64859d9b869b063ddcd2
2010-12-03 18:12:26

Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...

More Articles (3 articles) »
Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'